KCTD11 and neoplasm: Mutations within the components of the HH pathway, for example, membrane receptor proteins PTCH1 and SMO [34, 35], non-membrane receptor proteins, such as SUFU [36, 37] and REN (KCTD11) [38], disrupt the feedback loop causing activation of HH pathway and tumor progression.